In the PSP patient retention was highest in the basal ganglia and the midbrain.49 While retention of [18F]THK-5317 reflects the known tau pathology of CBD and PSP, further investigation must be performed with a larger sample size to determine its utility in these disorders and establish any correlations with clinical measures, such as motor scores and cognition. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.